AU2008236993A1 - Method of treating brain cancer - Google Patents

Method of treating brain cancer Download PDF

Info

Publication number
AU2008236993A1
AU2008236993A1 AU2008236993A AU2008236993A AU2008236993A1 AU 2008236993 A1 AU2008236993 A1 AU 2008236993A1 AU 2008236993 A AU2008236993 A AU 2008236993A AU 2008236993 A AU2008236993 A AU 2008236993A AU 2008236993 A1 AU2008236993 A1 AU 2008236993A1
Authority
AU
Australia
Prior art keywords
methyl
administered
methoxy
quinazolin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008236993A
Other languages
English (en)
Inventor
Mark Laughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myrexis Inc
Original Assignee
Myrexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myrexis Inc filed Critical Myrexis Inc
Publication of AU2008236993A1 publication Critical patent/AU2008236993A1/en
Assigned to MYREXIS, INC. reassignment MYREXIS, INC. Amend patent request/document other than specification (104) Assignors: MYRIAD PHARMACEUTICALS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008236993A 2007-04-10 2008-04-10 Method of treating brain cancer Abandoned AU2008236993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91097507P 2007-04-10 2007-04-10
US60/910,975 2007-04-10
PCT/US2008/059905 WO2008124822A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Publications (1)

Publication Number Publication Date
AU2008236993A1 true AU2008236993A1 (en) 2008-10-16

Family

ID=39831435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008236993A Abandoned AU2008236993A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Country Status (9)

Country Link
US (1) US20100129470A1 (cg-RX-API-DMAC10.html)
EP (1) EP2144504A4 (cg-RX-API-DMAC10.html)
JP (1) JP2010523696A (cg-RX-API-DMAC10.html)
KR (1) KR20100016385A (cg-RX-API-DMAC10.html)
CN (1) CN101742910A (cg-RX-API-DMAC10.html)
AU (1) AU2008236993A1 (cg-RX-API-DMAC10.html)
CA (1) CA2720982A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ580866A (cg-RX-API-DMAC10.html)
WO (1) WO2008124822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772358A (zh) * 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
NZ580867A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating melanoma
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2010006115A1 (en) * 2008-07-11 2010-01-14 Myriad Pharmaceuticals, Inc. Pharmaceutical compounds as cytotoxic agents and the use thereof
US20110224240A1 (en) * 2010-01-11 2011-09-15 Myrexis, Inc. Methods of treating cancer and related diseases
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
WO2014197569A1 (en) * 2013-06-05 2014-12-11 Cytrx Corporation Cytotoxic agents for the treatment of cancer
CN105288629B (zh) * 2014-05-28 2021-02-19 北京大学 具有药效叠加作用及毒性分散效应的组合药物
GB2553716B (en) * 2015-04-17 2020-06-17 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents
IL278311B2 (en) * 2018-05-02 2024-02-01 Tel Hashomer Medical Res Infrastructure & Services Ltd Preparations and methods for the treatment of glioblastoma
IL325918A (en) * 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102793A3 (en) * 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US7001926B2 (en) * 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
BR0212897A (pt) * 2001-09-21 2004-08-24 Univ Tulane Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
CA2531327A1 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
AU2006204052A1 (en) * 2005-01-03 2006-07-13 Cytovia, Inc. Method of treating brain cancer
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
CN102772358A (zh) * 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580867A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating melanoma
WO2009023876A1 (en) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Method of treating non-small cell lung cancer

Also Published As

Publication number Publication date
US20100129470A1 (en) 2010-05-27
WO2008124822A1 (en) 2008-10-16
EP2144504A1 (en) 2010-01-20
NZ580866A (en) 2011-02-25
CN101742910A (zh) 2010-06-16
KR20100016385A (ko) 2010-02-12
EP2144504A4 (en) 2012-10-03
JP2010523696A (ja) 2010-07-15
CA2720982A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
US20100129470A1 (en) Method of treating brain cancer
JP6172865B2 (ja) 併用療法によるプロカスパーゼ３活性化
JP2001247459A (ja) 癌の組み合わせ療法
EP3277284B1 (en) Novel therapies for cancer
US20100087457A1 (en) Dosages and methods for the treatment of cancer
JP2013501808A (ja) アポトーシスを促進し、かつ転移を阻害する方法
US20100087458A1 (en) Method of treating melanoma
JP2014058572A (ja) Ｈｋｉ−２７２とビノレルビンとを含有する抗悪性腫瘍剤の組合せ
US20100261739A1 (en) Method of Treating Non-Small Cell Lung Cancer
US20100093773A1 (en) Methods of treating cancer
JP2011512399A (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
CA2944255A1 (en) New derivatives of cephalosporin for treating cancer
EP3787661B1 (en) Combination of temozolomide and a par-1 conjugate for treating glioblastoma
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
WO2025076094A1 (en) Egfr inhibitors of formula (i) for use in methods of treating cancer having two or more mutations in egfr
WO2009104152A1 (en) Combination treatment for ovarian cancer
HK1245120B (en) Novel therapies for cancer
JPH11217338A (ja) キノリン誘導体を用いる医薬品の効果改善および増強剤
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application